Revvity, Inc. (RVTY)
Health Care · Health Care Equipment · US stock · S&P 500 component
$152.64
▼ -2.07 (1.34%)
Fair valueOvervalued
$57 −62.8% to fair value
$28fair band $34–$79$85
Day's range
$151.61 – $155.50
52-week range
$81.17 – $166.25
About Revvity, Inc.
Revvity is a life sciences and diagnostics company that was formerly known as PerkinElmer. It supplies instruments, reagents, software and services used by researchers and drug developers, and it provides diagnostic tests including newborn and prenatal screening and immunodiagnostics. Customers are pharmaceutical and biotechnology firms, academic laboratories, hospitals, clinical laboratories and public health bodies. The business is organised into life sciences and diagnostics segments.
Revenue of $2.9 billion over the last twelve months comes from recurring reagents and tests, instruments and software. Revenue has changed at -4.8% a year across the last three years. The operating margin is 12.3%, the business earns 3% on the capital invested in it, and net debt is 2.8 times EBITDA. The dividend yield is 0.2%. On the site's X-Ray Score it receives 24 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $81.17 – $166.25Volume 1,336,300Daily, split-adjusted
Vitals
Market cap$17.0B
52-week range$81.17 – $166.25
Volume (last day)1,336,300
P/E (TTM)73.2
EBIT / EV yield1.9%
Free-cash-flow yield3.3%
Dividend yield0.2%
Revenue (TTM)$2.9B
Net income (TTM)$238M
Operating margin12.3%
Return on capital3.4%
Debt incl. leases$3.2B
Cash & securities$1.0B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$57model spread $44 – $57
Overvalued
−62.8% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Price $153
Undervalued < $34Fair $34 – $79Overvalued > $79
10-year DCF (market-scaled) · excluded
$16
Peer multiples
$59
Earnings power floor (not blended)
$29
Fundamentals-adjusted multiple
$55
Growth the price implies
31.3%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
15/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield1.9%
Free-cash-flow yield3.3%
Fair value vs price0.4×
Growth
Weak
19/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)-4.8%
EPS growth (3y)-22.8%
Growth consistency80%
Profitability
Weak
25/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital3.4%
Operating margin12.3%
Financial health
Weak
39/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA2.8×
Interest cover3.8×
Dividends
Weak
29/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.2%
Dividends vs free cash flow6%
Dividend growth-2.5%
Quarterly results: last 6 quarters
+2.3%
Mar '25
+4.1%
Jun '25
+2.2%
Sep '25
+5.9%
Dec '25
+7.0%
Apr '26
+1.3%
Jul '26
Revenue against the same quarter a year earlier. Latest quarter revenue $730M, diluted EPS $0.47.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 1 Good · ● 4 Average · ● 10 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldBad
Risk models
Altman Z''Average
Piotroski F-ScoreBad
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioGood
Net debt / EBITDAAverage
Interest coverBad
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 26/100.
Financials
| FY22 | FY23 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.3B | $2.8B | $2.8B | $2.9B |
| Operating income | $1.3B | $743M | $301M | $347M | $357M |
| Net income | $943M | $569M | $693M | $270M | $241M |
| Operating cash flow | $1.4B | $680M | $91M | $628M | $583M |
| Operating margin | 32.9% | 22.4% | 10.9% | 12.6% | 12.5% |
| Free cash flow | $1.3B | $594M | $10M | $542M | $509M |
| Diluted EPS | $8.08 | $4.50 | $5.55 | $2.20 | $2.07 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
9 bullish · 4 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 154.1 | Bearish |
| EMA 10 | 153.1 | Bearish |
| SMA 20 | 151.4 | Bullish |
| EMA 20 | 149.8 | Bullish |
| SMA 50 | 136.1 | Bullish |
| EMA 50 | 138.6 | Bullish |
| SMA 100 | 121.8 | Bullish |
| EMA 100 | 126.5 | Bullish |
| SMA 200 | 109.0 | Bullish |
| EMA 200 | 115.3 | Bullish |
Oscillators (daily)
| RSI (14) | 59.26 | Neutral |
| MACD (12, 26) | 5.17 | Bullish |
| Momentum (12) | -0.16 | Bearish |
| Stochastic %K (14) | 30.38 | Neutral |
| Williams %R (14) | -69.62 | Neutral |
| CCI (20) | 40.33 | Neutral |
Pivot points (classic, last session)
S3 147.1 | S2 149.4 | S1 151.0 | Pivot 153.3 | R1 154.9 | R2 157.1 | R3 158.8 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.21 USD
Yield on today's price
0.14%
Frequency
Quarterly
Next ex-dividend date
23 Oct 2026
| Ex-dividend date | Amount per share |
|---|---|
| 23 Oct 2026 (upcoming) | 0.0700 |
| 17 Jul 2026 | 0.0700 |
| 17 Apr 2026 | 0.0700 |
| 16 Jan 2026 | 0.0700 |
| 17 Oct 2025 | 0.0700 |
| 18 Jul 2025 | 0.0700 |
| 17 Apr 2025 | 0.0700 |
| 17 Jan 2025 | 0.0700 |
| 18 Oct 2024 | 0.0700 |
| 19 Jul 2024 | 0.0700 |
| 18 Apr 2024 | 0.0700 |
| 18 Jan 2024 | 0.0700 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
RVTY SEC filings
11 Aug 2026
10-QSEC EDGAR
Quarterly report
4 Aug 2026
8-KSEC EDGAR
Results of operations; Other events
12 May 2026
10-QSEC EDGAR
Quarterly report
5 May 2026
8-KSEC EDGAR
Results of operations; Other events
1 May 2026
8-KSEC EDGAR
Shareholder vote results
16 Mar 2026
DEF 14ASEC EDGAR
Proxy statement
24 Feb 2026
10-KSEC EDGAR
Annual report
2 Feb 2026
8-KSEC EDGAR
Results of operations
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.